Maxim Group analyst Jason McCarthy maintained a Buy rating on Omeros Corp (NASDAQ: OMER) today and set a price target of $32. The company’s shares opened today at $22.75, close to its 52-week high of $25.20.
McCarthy commented:
“Omeros announced that the European Commission has granted Transplant (HSCT). This is the second EU orphan designation for OMS721, the first being IgA Nephropathy, note that the FDA has granted orphan designations for both aforementioned indications.”
According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 15.4% and a 47.7% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
Currently, the analyst consensus on Omeros Corp is a Strong Buy with an average price target of $29.
See today’s analyst top recommended stocks >>
The company has a one-year high of $25.20 and a one-year low of $8.36. Currently, Omeros Corp has an average volume of 580.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Omeros Corp. operates as a biopharmaceutical company specializes in discovery, development, and commercializes of both small-molecule and protein therapeutics for large -market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system.
